Were Analysts Bullish Charles River Laboratories International, Inc

Doris Richards
December 7, 2017

Riverhead Capital Management LLC now owns 1,931 shares of the medical research company's stock worth $195,000 after purchasing an additional 247 shares during the last quarter. The medical research company reported $1.29 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.14 by $0.15. Schwab Charles Corp New now has $69.11 billion valuation. Walleye Trading Ltd Limited Liability Company owns 94 shares. About 152,703 shares traded or 2.34% up from the average. Bank of America Corporation (NYSE:BAC) has risen 58.64% since December 6, 2016 and is uptrending. It has outperformed by 152.93% the S&P500.

A number of research analysts have recently commented on CRL shares. The institutional investor owned 4,304 shares of the medical research company's stock after selling 1,046 shares during the period. During the same quarter past year, the company posted $1.18 earnings per share. The MF Rank of Charles River Laboratories International, Inc. The stock decreased 2.13% or $2.22 during the last trading session, reaching $102.07. About 107,997 shares traded. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Charles River Laboratories International by 12.7% in the 2nd quarter. (NYSE:CRL) has a Piotroski F-Score of 7. It has underperformed by 9.64% the S&P500.

Olstein Capital Management Lp increased Scripps Networks Interact In (NYSE:SNI) stake by 110,580 shares to 208,380 valued at $14.23M in 2017Q2. Constellation Brands Inc (NYSE:STZ) was reduced too.

Investors sentiment increased to 1.37 in Q2 2017. Its up 0.27, from 1.03 in 2017Q1. It worsened, as 79 investors sold BAC shares while 543 reduced holdings. Raymond James & reported 3,734 shares stake. Jefferies Limited Liability invested in 0% or 7,185 shares. Fsi Ltd Liability Company has invested 3.1% in Bank of America Corporation (NYSE:BAC). Similarly, investors look up the share price over 12 month periods. Green Square Capital Lc invested in 10,704 shares or 0.08% of the stock. City Holdg has 1,303 shares. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Price T Rowe Assocs Md accumulated 354,338 shares. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. Weaver C Barksdale Assoc accumulated 98 shares. If the Golden Cross is greater than 1, then the 50 day moving average is above the 200 day moving average - indicating a positive share price momentum. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Charles Schwab had 74 analyst reports since August 11, 2015 according to SRatingsIntel. (NYSE:CRL) on Thursday, June 29 with "Buy" rating. The firm has "Sell" rating by UBS given on Tuesday, September 6. The rating was maintained by Deutsche Bank on Monday, July 18 with "Buy". Generally, a higher P/CF ratio indicates that the company is less capital demanding and the lesser price to cash flow indicates that the company is more capital demanding. Argus Research initiated The Charles Schwab Corporation (NYSE:SCHW) on Wednesday, March 23 with "Buy" rating. Jefferies maintained The Charles Schwab Corporation (NYSE:SCHW) rating on Friday, September 15. The company has a consensus rating of "Buy" and a consensus target price of $106.63. (NYSE:KMG) was sold by HATCHER DAVID L on Friday, June 16. The stock of The Charles Schwab Corporation (NYSE:SCHW) earned "Buy" rating by Suntrust Robinson on Monday, December 19. It also increased its holding in Du Pont E I De Nemours & Co (NYSE:DD) by 16,460 shares in the quarter, for a total of 389,757 shares, and has risen its stake in Vanguard Intl Equity Index F (VNQI). During the same period last year, the company posted $1.18 EPS. equities analysts expect that Charles River Laboratories International, Inc. will post 5.13 earnings per share for the current year. The medical research company reported $1.30 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.22 by $0.08. CRL's profit will be $61.10M for 19.81 P/E if the $1.29 EPS becomes a reality. The price to earnings ratio for Charles River Laboratories International, Inc.


Investors sentiment decreased to 1.12 in Q2 2017. Its up 0.48, from 0.89 in 2017Q1. NYSE:CRL is 0.054086. Earnings Yield helps investors measure the return on investment for a given company. 45 funds opened positions while 110 raised stakes. Gemmer Asset Limited Liability Com, a California-based fund reported 156 shares. Cadence Cap Ltd Com has 17,500 shares for 0.12% of their portfolio. Cambridge Advisors Inc. acquired a new stake in Charles River Laboratories International during the 2nd quarter valued at $202,000. (NYSE:CRL) has a current ERP5 Rank of 6151. Boltwood Mngmt has 11,262 shares for 0.18% of their portfolio.

WESCAP Management Group Inc. lessened its stake in Charles River Laboratories International, Inc. Pacad Limited has invested 0.01% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL) is -0.006365. This percentage is calculated by adding the dividend yield plus the percentage of shares repurchased. Charles River Laboratories Intl. has a 52-week low of $67.20 and a 52-week high of $93.08. (NYSE:CRL). Gabelli Funds Llc holds 13,500 shares. Tiaa Cref Inv Ltd Llc accumulated 311,649 shares. Principal Financial Group Inc. boosted its position in shares of Charles River Laboratories International by 2.5% in the third quarter.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, November 9th. (NYSE:CRL) now has a Montier C-score of 1.00000. The VC1 of Charles River Laboratories International, Inc. Zacks Investment Research raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $110.00 price target for the company in a research report on Thursday, August 10th. Therefore 47% are positive. On Monday, November 13 the stock rating was maintained by Jefferies with "Buy". The firm earned "Buy" rating on Tuesday, July 21 by Jefferies. The FCF Growth of Charles River Laboratories International, Inc. (NYSE:CRL) on Friday, August 28 with "Outperform" rating. The rating was maintained by BMO Capital Markets on Monday, October 16 with "Market Perform". The firm has "Equal Weight" rating given on Wednesday, November 30 by Barclays Capital. (NYSE:CRL) on Friday, January 8 with "Outperform" rating. (NYSE:CRL) rating on Friday, January 8. The company was maintained on Thursday, November 16 by SunTrust.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER